



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

29 November 2024
EMA/174789/2024

Agenda – 13th Industry stakeholder platform on research and development support

2 December 2024, 12:30 – 17:00 (room 0B and Webex)

Co-chairs: Michael Berntgen and Iordanis Gravanis

Item	Agenda	Time
1.	Welcome / Introductions <ul style="list-style-type: none">• Overview of the agenda• Review of status of follow-up actions from the last platform meeting <i>Michael Berntgen (EMA)</i>	12:30 – 12:40
2.	Experience with Portfolio and Technology meetings (PTMs) <ul style="list-style-type: none">• Summary of first experiences• Next steps for refinement based on feedback received <i>Enrico Tognana (EMA)</i> Discussion	12:40 – 13:00
3.	Development support offering for programme-specific evidence planning A. Update from EMA on recent developments <ul style="list-style-type: none">• Latest developments in terms of discussion meetings in scientific advice• First experience with consolidated SAWP/CTCG advice on clinical trials• Update about the development of the survey on the ongoing PRIME pilots• Progress with the Action plan on future-proofing the Qualification of Novel Methodologies• Status of activities relate to evidence planning for combination developments <i>Iordanis Gravanis (EMA)</i> B. Industry reflections on selected topics <ul style="list-style-type: none">• Review of options on better use of SA discussion meetings alongside the development of metrics for measuring effectiveness of the process <i>Alexa Hunter (Industry)</i> <ul style="list-style-type: none">• Expectations regarding the consolidated SAWP/CTCG advice on clinical trials <i>Laura Oliveira (Industry)</i> Discussion	13:00 – 13:25 13:25 – 13:45 13:45 – 14:15

Coffee break		15 min
4.	<p>Supporting paediatric developments</p> <p>A. Paediatric Scientific Advice</p> <ul style="list-style-type: none"> • Clarifications in the scientific advice guidance based on the comments received from industry • Strengthening of the use of scientific pre-submission meetings for complicated PIPs • Review of the requirements for paediatric scientific advice <p><i>Ralph Bax, Iordanis Gravanis, Chrissi Pallidis (EMA)</i> <i>Alexa Hunter (Industry)</i></p> <p>Discussion</p> <p>B. Stepwise PIP pilot</p> <ul style="list-style-type: none"> • Update on progress and preliminary learnings • Development of proposals for analysing the pilot experience <p><i>Chrissi Pallidis (EMA)</i> <i>Gesine Bejeuhr (Industry)</i></p> <p>Discussion</p>	<p>14:30 – 14:55</p> <p>14:55 – 15:15</p> <p>15:15 – 15:30</p> <p>15:30 – 15:50</p>
5.	<p>Focus group to explore opportunities for the use of Real-World Data (RWD) and the generation of Real-World Evidence (RWE)</p> <ul style="list-style-type: none"> • Overview of objectives and next steps <p><i>Patrice Verpillat (EMA)</i></p>	15:50 – 16:05
6.	<p>Operational update</p> <p>A. Processing Scientific Advice requests regarding New Fee Regulation</p> <ul style="list-style-type: none"> • Guidance from January 2025 <p><i>Tarita Toufexi (EMA)</i></p> <p>B. Onboarding of paediatric procedures onto IRIS</p> <ul style="list-style-type: none"> • Status update • Fixing of issues identified by applicants <p><i>Tarita Toufexi (EMA)</i></p>	<p>16:05 – 16:20</p> <p>16:20 – 16:35</p>
7.	<p>Summary of follow-up items / Close of the meeting</p> <p><i>Michael Berntgen (EMA)</i></p>	16:35 – 16:45